통합검색
내가 찾은 검색어
'Tumor-targeting' 에 대한 통합검색결과 146건입니다.
한빛사146건
-
Modulation of tumor inflammatory signaling and drug sensitivity by CMTM4
- EMBO J. 13 February 2025 | https://doi.org/10.1038/s44318-024-00330-y
- 2025.02
-
Zinc ferrite nanoparticle with enhanced magnetic attraction for controlled drug delivery and in vivo tumor therapy
- Chem. Eng. J. Volume 503, 1 January 2025, 158311 | https://doi.org/10.1016/j.cej.2024.158311
- 2025.01
- 바이오·의료융합
-
Enhancing glioblastoma therapy via intranasal administration of highly potent cell-penetrating peptide decorated nanoparticles
- J. Control. Release Jan 02 2025, 378 S0168-3659(24)00913-1 | https://doi.org/10.1016/j.jconrel.2024.12.058
- 2025.01
-
Targeted nanoparticle delivery unleashes synergistic photothermal and immunotherapeutic effects against hepatocellular carcinoma
- J. Nanobiotechnol. Dec 19 2024, 22 (1) 778 | https://doi.org/10.1186/s12951-024-03030-1
- 2024.12
- 바이오·의료융합
-
-
Anti-PD-L1 Antibody Fragment Linked to Tumor-Targeting Lipid Nanoparticle Can Eliminate Cancer and Its Metastasis via Photoimmunotherapy
- ACS Nano Nov 27 2024, | https://doi.org/10.1021/acsnano.4c08448
- 2024.11
- 바이오·의료융합
-
Self-assembled Peptide-derived Proteolysis-targeting Chimera (PROTAC) Nanoparticles for Tumor-targeted and Durable PD-L1 Degradation in Cancer Immunot
- Angew. Chem.-Int. Edit. Nov 21 2024, | https://doi.org/10.1002/anie.202414146
- 2024.11
- 바이오·의료융합
-
Improved safety of chimeric antigen receptor T cells indirectly targeting antigens via switchable adapters
- Nat. Commun. 18 November 2024 | https://doi.org/10.1038/s41467-024-53996-7
- 2024.11
- 의약학
-
Synergistic anticancer immunity in metastatic triple-negative breast cancer through an in situ amplifying Peptide-Drug Conjugate
- J. Control. Release Volume 375 , November 2024, Pages 681-697 | https://doi.org/10.1016/j.jconrel.2024.07.074
- 2024.11
- 의약학
-
Single-cell multiomics analysis reveals dynamic clonal evolution and targetable phenotypes in acute myeloid leukemia with complex karyotype
- Nat. Genet. 25 November 2024 | https://doi.org/10.1038/s41588-024-01999-x
- 2024.11
-
Rational Design of Biocompatible Ir(III) Photosensitizer to Overcome Drug-Resistant Cancer via Oxidative Autophagy Inhibition
- Adv. Sci. Nov 14 2024, | https://doi.org/10.1002/advs.202407236
- 2024.11
- 생명과학
-
Smart Accumulating Dual-Targeting Lipid Envelopes Equipping Oncolytic Adenovirus for Enhancing Cancer Gene Therapeutic Efficacy
- ACS Nano Oct 02 2024, | https://doi.org/10.1021/acsnano.4c02165
- 2024.10
- 생명과학
-
CD13-targeting and TRAIL-displaying protein nanoparticles effectively induce apoptotic cell death of acute myeloid leukemia, prolonging survival in mo
- Nano Today Available online 4 September 2024 | https://doi.org/10.1016/j.nantod.2024.102474
- 2024.09
- 생명과학
-
RNA-Activatable Near-Infrared Photosensitizer for Cancer Therapy
- J. Am. Chem. Soc. Aug 31 2024, | https://doi.org/10.1021/jacs.4c09470
- 2024.08
-
Dual alarmin-receptor-specific targeting peptide systems for treatment of sepsis
- Acta Pharm. Sin. B Available online 19 August 2024 | https://doi.org/10.1016/j.apsb.2024.08.015
- 2024.08
- 생명과학
-
Systemic Brain Delivery of Oligonucleotide Therapeutics Enhanced by Protein Corona-Assisted DNA Cubes
- Small Methods Aug 02 2024, | https://doi.org/10.1002/smtd.202400902
- 2024.08
- 의약학
-
Lutetium Texaphyrin-Celecoxib Conjugate as a Potential Immuno-Photodynamic Therapy Agent
- J. Am. Chem. Soc. Jul 03 2024, | https://doi.org/10.1021/jacs.4c05978
- 2024.07
- 바이오·의료융합
-
Targeted delivery of anti-miRNA21 sensitizes PD-L1high tumor to immunotherapy by promoting immunogenic cell death
- Theranostics 2024 Jun 17;14(10):3777-3792 | https://doi.org/10.7150/thno.97755
- 2024.06
- 바이오·의료융합
-
Intravesical instillation-based mTOR-STAT3 dual targeting for bladder cancer treatment
- J. Exp. Clin. Cancer Res. Jun 18 2024, 43 (1) | https://doi.org/10.1186/s13046-024-03088-7
- 2024.06
- 의약학
-
Light-Triggered PROTAC Nanoassemblies for Photodynamic IDO Proteolysis in Cancer Immunotherapy
- Adv. Mater. Jun 19 2024, | https://doi.org/10.1002/adma.202405475
- 2024.06
- 바이오·의료융합
